MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Cisplatin (Platinol ®)

Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)

Journal of Surgical Oncology 2017 November 28 [Epub ahead of print] [Link] Fisher SB, Rafeeq S, Hess K, Grotz TE, Mansfield P, Royal R, Badgwell B, Fleming J, Fournier K, Mann GN Abstract BACKGROUND: Elevated BNP is associated with adverse cardiac outcomes after noncardiac surgery. We assessed BNP values as markers of perioperative fluid status […]

Comments Off on Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC)

Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report

Journal of Nippon Medical School 2017 [Link] Hisakane K, Ohmatsu H, Umemura S, Kirita K, Matsumoto S, Yoh K, Niho S, Goto K Abstract Cell-free and concentrated ascites reinfusion therapy (CART) is recognized as a useful treatment to improve the symptoms caused by refractory ascites. Recently, a few clinical studies have reported the effects of […]

Comments Off on Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report

A review of bevacizumab in the treatment of malignant pleural mesothelioma

Future Oncology 2017 September [Epub ahead of print] [Link] Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, […]

Comments Off on A review of bevacizumab in the treatment of malignant pleural mesothelioma

A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.

Journal of Korean Medical Science 2017 November [Link] Kim JS, Lim SY, Hwang J, Kang EJ, Choi YJ Abstract Primary pericardial malignant mesothelioma (PPM) is a very rare malignancy, with an incidence of less than 0.002% and represents less than 5% of all mesotheliomas. The cause of pericardial mesothelioma is uncertain that differ from pleural […]

Comments Off on A Case Report of Primary Pericardial Malignant Mesothelioma Treated with Pemetrexed and Cisplatin.

Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells

Cancer Medicine 2017 September [Epub ahead of print] [Link] Yamaji M, Ota A, Wahiduzzaman M, Karnan S, Hyodo T, Konishi H, Tsuzuki S, Hosokawa Y, Haniuda M Abstract Malignant pleural mesothelioma (MPM), an asbestos-related occupational disease, is an aggressive and incurable tumor of the thoracic cavity. Despite recent advances in MPM treatment, overall survival of […]

Comments Off on Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of Clinical Oncology 2017 September 11 [Epub ahead of print] [Link] Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G Abstract Purpose LUME-Meso is a phase […]

Comments Off on Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response

Asian Pacific Journal of Cancer Prevention 2017 August [Link] Rahouma M, Aziz H, Ghaly G, Kamel M, Loai I, Mohamed A Abstract Purpose: Malignant pleural mesothelioma (MPM) has a poor prognosis in general. Here we sought to evaluate prognostic factors and predictors of response to chemotherapy in good performance (PS=0-I) patients. Methods: We retrospectively reviewed […]

Comments Off on Survival in Good Performance Malignant Pleural Mesothelioma Patients; Prognostic Factors and Predictors of Response

Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

OncoTargets and Therapy 2017 June [Link] Aigner KR, Selak E, Gailhofer S Abstract INTRODUCTION: Therapy of malignant pleural mesothelioma and especially the adequate role of surgery in this context remain the subject of controversial discussions. Radical surgery in particular, which is associated with substantial morbidity, failed to translate into a definite survival advantage. We report […]

Comments Off on Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

OncoTargets and Therapy 2017 June [Link] Aigner KR, Selak E, Gailhofer S Abstract INTRODUCTION: Therapy of malignant pleural mesothelioma and especially the adequate role of surgery in this context remain the subject of controversial discussions. Radical surgery in particular, which is associated with substantial morbidity, failed to translate into a definite survival advantage. We report […]

Comments Off on Isolated thoracic perfusion with chemofiltration for progressive malignant pleural mesothelioma

Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Lung Cancer 2017 August [Epub 2017 May 12] [Link] Zhan M, Zheng H, Xu T, Yang Y, Li Q Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable […]

Comments Off on Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial